114 related articles for article (PubMed ID: 20484615)
1. A model for glucose, insulin, and beta-cell dynamics in subjects with insulin resistance and patients with type 2 diabetes.
Ribbing J; Hamrén B; Svensson MK; Karlsson MO
J Clin Pharmacol; 2010 Aug; 50(8):861-72. PubMed ID: 20484615
[TBL] [Abstract][Full Text] [Related]
2. Beta-cell function and mass in type 2 diabetes.
Larsen MO
Dan Med Bull; 2009 Aug; 56(3):153-64. PubMed ID: 19728971
[TBL] [Abstract][Full Text] [Related]
3. The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin.
Tonstad S; Retterstøl K; Ose L; Ohman KP; Lindberg MB; Svensson M
Metabolism; 2007 Sep; 56(9):1285-92. PubMed ID: 17697874
[TBL] [Abstract][Full Text] [Related]
4. Protection of pancreatic beta-cells: is it feasible?
Bonora E
Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):74-83. PubMed ID: 18096375
[TBL] [Abstract][Full Text] [Related]
5. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
6. Insulin resistance, beta-cell function, and glucose tolerance in Brazilian adolescents with obesity or risk factors for type 2 diabetes mellitus.
da Silva RC; Miranda WL; Chacra AR; Dib SA
J Diabetes Complications; 2007; 21(2):84-92. PubMed ID: 17331856
[TBL] [Abstract][Full Text] [Related]
7. Dynamics of insulin sensitivity, -cell function, and -cell mass during the development of diabetes in fa/fa rats.
Topp BG; Atkinson LL; Finegood DT
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1730-5. PubMed ID: 17895283
[TBL] [Abstract][Full Text] [Related]
8. The impact of sulfonylurea treatment upon the mechanisms responsible for the insulin resistance in type II diabetes.
Kolterman OG; Olefsky JM
Diabetes Care; 1984; 7 Suppl 1():81-8. PubMed ID: 6376033
[TBL] [Abstract][Full Text] [Related]
9. Fate of the beta-cell in the pathophysiology of type 2 diabetes.
Campbell RK
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S10-5. PubMed ID: 19801360
[TBL] [Abstract][Full Text] [Related]
10. Initiating insulin in patients with type 2 diabetes.
Aoki TJ; White RD
J Fam Pract; 2007 Aug; 56(8 Suppl Hot Topics):S12-20. PubMed ID: 18667139
[TBL] [Abstract][Full Text] [Related]
11. Beta cell function and insulin sensitivity in women with polycystic ovary syndrome: influence of the family history of type 2 diabetes mellitus.
Vrbikova J; Bendlova B; Vankova M; Dvorakova K; Grimmichova T; Vondra K; Pacini G
Gynecol Endocrinol; 2009 Sep; 25(9):597-602. PubMed ID: 19572227
[TBL] [Abstract][Full Text] [Related]
12. Homeostasis model assessment (HOMA) as surrogate insulinization criteria in patients with type 2 diabetes.
Bermúdez V; Cano R; Cano C; Bermúdez F; Leal E; Acosta K; Mengual E; Arraiz N; Briceño C; Gómez J; Bustamante M; Aparicio D; Cabrera M; Valdelamar L; Rodriguez M; Manuel V; Hernández R
Am J Ther; 2008; 15(4):409-16. PubMed ID: 18645347
[TBL] [Abstract][Full Text] [Related]
13. Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice.
Harrity T; Farrelly D; Tieman A; Chu C; Kunselman L; Gu L; Ponticiello R; Cap M; Qu F; Shao C; Wang W; Zhang H; Fenderson W; Chen S; Devasthale P; Jeon Y; Seethala R; Yang WP; Ren J; Zhou M; Ryono D; Biller S; Mookhtiar KA; Wetterau J; Gregg R; Cheng PT; Hariharan N
Diabetes; 2006 Jan; 55(1):240-8. PubMed ID: 16380499
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic-pharmacodynamic assessment of the interrelationships between tesaglitazar exposure and renal function in patients with type 2 diabetes mellitus.
Hamrén B; Ohman KP; Svensson MK; Karlsson MO
J Clin Pharmacol; 2012 Sep; 52(9):1317-27. PubMed ID: 22045829
[TBL] [Abstract][Full Text] [Related]
15. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.
Mu J; Woods J; Zhou YP; Roy RS; Li Z; Zycband E; Feng Y; Zhu L; Li C; Howard AD; Moller DE; Thornberry NA; Zhang BB
Diabetes; 2006 Jun; 55(6):1695-704. PubMed ID: 16731832
[TBL] [Abstract][Full Text] [Related]
16. Assessing progression to impaired glucose tolerance and type 2 diabetes mellitus.
Guerrero-Romero F; Rodríguez-Morán M
Eur J Clin Invest; 2006 Nov; 36(11):796-802. PubMed ID: 17032347
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic beta-cell function and insulin sensitivity in japanese subjects with impaired glucose tolerance and newly diagnosed type 2 diabetes mellitus.
Kanauchi M; Nakajima M; Saito Y; Kanauchi K
Metabolism; 2003 Apr; 52(4):476-81. PubMed ID: 12701062
[TBL] [Abstract][Full Text] [Related]
18. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study.
Wilson PW; Meigs JB; Sullivan L; Fox CS; Nathan DM; D'Agostino RB
Arch Intern Med; 2007 May; 167(10):1068-74. PubMed ID: 17533210
[TBL] [Abstract][Full Text] [Related]
19. Risk of progression to type 2 diabetes based on relationship between postload plasma glucose and fasting plasma glucose.
Abdul-Ghani MA; Williams K; DeFronzo R; Stern M
Diabetes Care; 2006 Jul; 29(7):1613-8. PubMed ID: 16801587
[TBL] [Abstract][Full Text] [Related]
20. Peroxisome proliferator-activated receptor (PPAR) delta genetic polymorphism and its association with insulin resistance index and fasting plasma glucose concentrations in Chinese subjects.
Hu C; Jia W; Fang Q; Zhang R; Wang C; Lu J; Xiang K
Diabet Med; 2006 Dec; 23(12):1307-12. PubMed ID: 17116180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
